BioCentury
ARTICLE | Company News

Action Pharma, Zealand Pharma, Abbott deal

June 25, 2012 7:00 AM UTC

Abbott completed the acquisition of AP214 and related IP from Action following the receipt of U.S. Antitrust clearance. Last year, the alpha-melanocyte-stimulating hormone analog met the primary endp...